← Leaderboards
Cara Lorene Loomis
University Of Michigan At Ann Arbor
$127,252
Attributed
$127,252
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.7K · FY2022–24$50K$37.5K$25K$12.5K$0
'22
'23
'24
Funding mix
By agency
NIH$127,252 · 1
By mechanism
F31$127,252 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Adina F Turcu$6,120,067
- Emily E Scott$11,885,415
- Pavan Reddy$35,237,005
- Alice Telesnitsky$37,945,631
- Patrice E. Fort$5,914,612
Others in their field
Other Rising Stars on “Immunosuppression”
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- John Parkinson · Thetis Pharmaceuticals, Llc$4,120,866
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- Martin Pule · University College London$3,627,871
- Amar Nijagal · University Of California, San Francisco$3,176,680
- Eric Holbrook · Miravista Diagnostics, Llc$2,971,862
Research focus
ImmunosuppressionAffinityActive SitesAdrenodoxinBiochemicalCardiovascular SystemCatalysisAldosteroneCortodoxoneBindingCyp11a1 GeneCyp11b1 GeneCytochrome P450DesignDistantDrug DesignComplexEnzymesFda ApprovedFutureHydrocortisoneHyperaldosteronismHypertensionInhibitor
Grant awards (4)
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushingâs Disease and Primary Aldosteronism Treatments$30,306
F31 · FY2024 · HD · contact PI
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushing's Disease and Primary Aldosteronism Treatments$2,500
F31 · FY2024 · HD · contact PI
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushingâs Disease and Primary Aldosteronism Treatments$47,694
F31 · FY2023 · HD · contact PI
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushingâs Disease and Primary Aldosteronism Treatments$46,752
F31 · FY2022 · HD · contact PI